These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7123576)

  • 1. Changes in plasma lipoprotein levels during medication with a glucoside-hydrolase inhibitor (acarbose).
    Homma Y; Irie N; Yano Y; Nakaya N; Goto Y
    Tokai J Exp Clin Med; 1982 May; 7(3):393-6. PubMed ID: 7123576
    [No Abstract]   [Full Text] [Related]  

  • 2. Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor.
    Nestel PJ; Bazelmans J; Reardon MF; Boston RC
    Diabete Metab; 1985 Oct; 11(5):316-7. PubMed ID: 4076509
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of acarbose on intestinal disaccharidase: review of its therapeutic potential].
    Sternberg A; Wagner Y; Fireman Z
    Harefuah; 1994 May; 126(9):527-9. PubMed ID: 8034269
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term effect of acarbose on diurnal serum triglyceride, glucose, insulin and adipose tissue lipoprotein lipase levels in patients with primary endogenous hypertriglyceridaemia, with or without type II diabetes.
    Noyon R; Pagano Mirani-Oostdijk C; van Gent CM; Frölich M; Hillebrand I; Terpstra J
    Neth J Med; 1986; 29(5):157-64. PubMed ID: 3520362
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor.
    Zavaroni I; Reaven GM
    Metabolism; 1981 Apr; 30(4):417-20. PubMed ID: 7010078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cholesterol and triglyceride content of lipoproteins in hyperlipoproteinemia type II/a, II/b and IV].
    Romics L; Karádi I; Simonyi E
    Orv Hetil; 1980 Oct; 121(43):2629-31. PubMed ID: 7208011
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of the alpha-glucosidase inhibitor, acarbose, on disaccharide splitting enzymes in human dental plaque.
    Fiehn NE; Moe D
    Scand J Dent Res; 1982 Apr; 90(2):124-30. PubMed ID: 6803351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Age-specific features of blood lipid and lipoprotein contents in patients with hypertension].
    Tokar' AV; Chaialo PP; Rudaia ES
    Ter Arkh; 1980; 52(8):11-4. PubMed ID: 7256575
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet.
    Walter-Sack IE; Wolfram G; Zöllner N
    Ann Nutr Metab; 1989; 33(2):100-7. PubMed ID: 2554784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cyclosporine and methylprednisolone on plasma lipoprotein levels in rats.
    Espino A; Lopez-Miranda J; Blanco-Cerrada J; Zambrana JL; Aumente MA; Paniagua JA; Blanco-Molina A; Jimenez-Pereperez JA; Rodriguez M; Pérez-Jiméz F
    J Lab Clin Med; 1995 Feb; 125(2):222-7. PubMed ID: 7844470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in Zucker (fafa) rats.
    Vasselli JR; Haraczkiewicz E; Maggio CA; Greenwood MR
    Pharmacol Biochem Behav; 1983 Jul; 19(1):85-95. PubMed ID: 6622510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
    Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
    Artery; 1982; 10(4):266-85. PubMed ID: 7181672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients ty pe 2 (NIDDM) (author's transl)].
    Laube H; Fouladfar M; Aubell R; Schmitz H
    Arzneimittelforschung; 1980; 30(7):1154-7. PubMed ID: 7191299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical use of alpha-glycosidase inhibitors.
    Erkelens DW
    Neth J Med; 1986; 29(5):155-6. PubMed ID: 3713938
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipoprotein profiles in a heterogeneous group of patients with nephrotic syndrome.
    Michaeli J; Bar-On H; Shafrir E
    Isr J Med Sci; 1981 Nov; 17(11):1001-8. PubMed ID: 7319786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients.
    Maruhama Y; Nagasaki A; Kanazawa Y; Hirakawa H; Goto Y; Nishiyama H; Kishimoto Y; Shimoyama T
    Tohoku J Exp Med; 1980 Dec; 132(4):453-62. PubMed ID: 7256727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary experiments on the effects of glucosidase inhibitor in fattening pigs].
    Bronsch K; Schneider D; Kühl K; Andrzejak N
    Z Tierphysiol Tierernahr Futtermittelkd; 1980; 44(1):36-46. PubMed ID: 7424206
    [No Abstract]   [Full Text] [Related]  

  • 18. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing enzymes and glycoproteins in streptozotocin-induced diabetic rats.
    Stanely Mainzen Prince P; Kannan NK
    J Pharm Pharmacol; 2006 Oct; 58(10):1373-83. PubMed ID: 17034661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipoproteins, apolipoproteins and intravenous fat tolerance in young athletes.
    Ericsson M; Johnson O; Tollin C; Furberg B; Backman C; Angquist K
    Scand J Rehabil Med; 1982; 14(4):209-12. PubMed ID: 7178868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of a alpha-glucosidases-inhibitor on energy metabolism of fattening pigs].
    Kirchgessner M; Müller HL; Roth FX
    Z Tierphysiol Tierernahr Futtermittelkd; 1980; 44(3):155-64. PubMed ID: 7445775
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.